Pharming Group N.V.
NASDAQ:PHARBiotechnology
+$0.28 today
- Market cap
- $882.43M
- Beta
- 0.10
- P/E (TTM)
- 77.0
- EPS (TTM)
- $0.02
Volume 0.01M
Average 0.01M
PHAR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Pharming Group N.V.NASDAQ: PHAR
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$4.41M, compared with $5.39M a year earlier. Trailing-twelve-month accounts receivables was -$13.18M.
Context
- Accounts receivables amounted to 0.9% of revenue in FY2025, down 1.4 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$4.41M or moves back toward the trailing-twelve-month quarterly average of -$3.29M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (3.36M) USD
- Year-over-year change
- +52.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.36M) | +52.1% |
| FY2024 | 2024-12-31 | (7.02M) | +62.1% |
| FY2023 | 2023-12-31 | (18.54M) | -884.2% |
| FY2022 | 2022-12-31 | 2.36M | -64.8% |
| FY2021 | 2021-12-31 | 6.71M | — |
Accounts Receivables vs competitors
How PHAR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +49.0% is the 3rd highest of 7, against a peer median of -29.7%.
- Accounts receivables amounts to 3.6% of revenue for PHAR, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $60.56B USD | +173755.7% | +40.6% | 5.9% | |
| LTM Sep 2026 | $63.73M USD | -14.2% | -10.4% | 6.6% | |
| LTM Jun 2026 | $17.47M USD | -45.2% | +19.7% | 1.9% | |
| LTM Mar 2026 | $13.18M USD | +49.0% | — | 3.6% | |
| LTM Mar 2026 | $8.33M USD | — | — | 904.4% | |
| LTM Mar 2026 | $4.8M USD | +1478.7% | — | 15.0% | |
| LTM Mar 2026 | $1.37M USD | -94.7% | -18.2% | 2.1% | |
| LTM Sep 2026 | €1.21M EUR | -592.3% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding PHAR) | — | -29.7% | +4.6% | 5.9% | |
Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 26.16M | 14.99M | (12.01M) | (8.79M) | 2.86M |
| Depreciation & Amortization | 22.23M | 13.19M | 15.93M | 16.64M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.27M | 6.39M | 9.25M | 11.65M | 0 |
| Change in Working Capital | (5.62M) | (387K) | (16.96M) | (10.43M) | 14.4M |
| Accounts Receivables | 6.71M | 2.36M | (18.54M) | (7.02M) | (3.36M) |
| Inventory | (6.98M) | (15.02M) | (14.43M) | (520.85K) | (1.29M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 17.87M |
| Other Working Capital | (5.36M) | 12.27M | 16.01M | (2.88M) | 1.19M |
| Other Non-Cash Items | (10.14M) | (11.72M) | (13.51M) | (10.92M) | 32.8M |
| Operating Cash Flow | 42.9M | 22.46M | (17.3M) | (1.86M) | 50.07M |
| Capital Expenditures | (18.95M) | (1.98M) | (1.46M) | (824.25K) | (751.09K) |
| Acquisitions (Net) | 0 | 7.3M | 0 | 0 | (65.53M) |
| Purchases of Investments | (5.2M) | 0 | (382.01M) | (294.4M) | 0 |
| Sales of Investments | 0 | 0 | 232.81M | 327.97M | 0 |
| Other Investing Activities | 0 | 0 | 21.28M | 0 | 84.72M |
| Investing Cash Flow | (24.15M) | 5.32M | (129.39M) | 32.74M | 18.43M |
| Debt Repayment | (3.65M) | (3.31M) | (4.04M) | (35.61M) | 0 |
| Common Stock Issued | 5.35M | 2.28M | 0 | 0 | 19.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (33.39M) | (3.95M) | 3M | (19.67K) | (5.39M) |
| Financing Cash Flow | (31.68M) | (4.98M) | (1.04M) | (35.63M) | 14.48M |
| Effect of Forex Changes | (2.07M) | (7.38M) | 2.13M | (2.29M) | 8.12M |
| Net Change in Cash | (15M) | 15.42M | (145.6M) | (7.04M) | 91.09M |
| Free Cash Flow | 23.95M | 20.48M | (18.77M) | (2.68M) | 49.31M |
Pharming Group N.V.
NASDAQ:PHAR
Intrinsic Alpha fair value
Locked
Current Price
$12.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.